Medical/Pharmaceuticals

Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases

Eccogene will receive initial upfront payment of $185 million. Eccogene is also eligible to receive up to$1.825 billion in future clinical, regulatory, and commercial milestones, as well as royalty payments. AstraZeneca will receive an exclusive license to develop and commercialize ECC5004 in al...

2023-11-09 15:05 1356

Noah Launches "Play The Full Game" Campaign with Singaporean Football Legend Fandi Ahmad as Brand Ambassador

SINGAPORE, Nov. 9, 2023 /PRNewswire/ -- Noah, the telehealth platform tailored for men and created by Ordinary Folk, is pleased to announce the launch of its "Play The Full Game" campaign and the appointment ofFandi Ahmad as Noah's brand ambassador. The campaign aims to empower men to have the co...

2023-11-09 14:31 2155

West Pharmaceutical Services Appoints Nilesh Shah as Vice President and General Manager of Emerging Markets

SINGAPORE, Nov. 9, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (West), a global leader in innovative solutions for injectable drug administration, today announced it has appointed Nilesh Shah to serve as Vice President and General Manager of Emerging Mark...

2023-11-09 12:58 9389

European Wellness and DXN Sign MoU to Establish World-Class Wellness Centre!

CYBERJAYA, Malaysia, Nov. 9, 2023 /PRNewswire/ -- European Wellness Biomedical Group (EW Group) has signed a Memorandum of Understanding with DXN Holdings Berhad (DXN) to jointly develop and establish a comprehensive wellness centre that draws from the extensive expertise and experience of both p...

2023-11-09 11:46 2647

DiscGenics Announces Research Collaboration with the U.S. Department of Veterans Affairs for Tissue-Engineered Discs with Discogenic Cells

Feasibility Project Awarded VA Technology Transfer Program BRAVE Funding SALT LAKE CITY, Nov. 9, 2023 /PRNewswire/ -- DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function...

2023-11-09 08:15 1992

Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023

HANGZHOU and SHAOXING, China, Nov. 9, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr.Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held atBoston, Unit...

2023-11-09 08:10 4636

WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan

SHANGHAI, Nov. 8, 2023 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, recei...

2023-11-09 08:00 2035

Holmusk Appoints Eze Abosi as Chief Growth Officer

New CGO joins Holmusk during a period of strong and sustainable growth for both the life science and payer/provider businesses. NEW YORK, Nov. 8, 2023 /PRNewswire/ -- Holmusk , a leading global behavioral health real-world evidence company, today announced that it has a...

2023-11-09 08:00 1671

Telix to Present at Jefferies London Healthcare Conference 2023

MELBOURNE, Australia, Nov. 9, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that DrChristian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies London Healthcare Conference 2023. The presentation will take place o...

2023-11-09 04:51 1782

Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema at American Academy of Ophthalmology

TAIPEI, Nov. 8, 2023 /PRNewswire/ --  * AG-73305 was found to be safe and tolerable with no severe adverse effects (SAEs) after a single intravitreal injection of doses of 0.5, 1, 2, and 4 mg in DME patients. * Data combining all 4 cohorts showed mean improvement in Best Corrected Visual Acc...

2023-11-08 23:23 1926

Porton Advanced Announces a Strategic Partnership with BioMap, with AI Models Facilitating AAV Gene Therapy Development

SUZHOU, China, Nov. 8, 2023 /PRNewswire/ -- On November 8, 2023, Porton Advanced announced the establishment of a strategic partnership with BioMap. BioMap will leverage Porton Advanced's unique Adeno-Associated Virus (AAV) vector technology platform and research data to develop AAV assembly effi...

2023-11-08 22:31 2198

Seoul National University Bundang Hospital (SNUBH) Secures Prestigious GHA Accreditation, Reinforcing Its Position as a Premier Global Medical Travel Destination

PALM BEACH GARDENS, Fla., Nov. 8, 2023 /PRNewswire/ -- Seoul National University Bundang Hospital (SNUBH), one of South Korea's most prestigious healthcare institutions, is delighted to announce that it has achieved a second consecutive term of Accreditation with Excellence fromGlobal Healthcare ...

2023-11-08 19:00 1908

The 2023 Asia Health and Life Sciences Innovation and Cooperation Summit Delivered Insights on the Future of Healthcare

SINGAPORE, Nov. 8, 2023 /PRNewswire/ -- The 2023 Asia Health and Life Sciences Innovation and Cooperation Summit (AHLSICS), hosted by ASK Health Asia and the SingHealth Duke-NUS Global Health Institute (SDGHI), in collaboration with the World Economic Forum, successfully concluded in Singapore on 1s...

2023-11-08 14:30 2530

Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region

MELBOURNE, Australia, Nov. 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed an exclusive agreement withDenmark-based WIIK Pharma ApS (Wiik Pharma) for the distribution of Telix's investigational prostate cancer imaging agent, Illuc...

2023-11-08 13:00 1713

Simulare Medical Launches the Alveolar Bone Graft Simulator

ABG Simulator New Addition to Further Support Cleft Reconstructive Surgical Training TAIPEI, Nov. 8, 2023 /PRNewswire/ -- Simulare Medical, a division of Smile Train Inc. (New York) announces the launch of the Alveolar Bone Graft (ABG) simulator, the latest high-fidelity surgical item in its gro...

2023-11-08 10:00 2123

SP Manufacturing expands into the United States

New Design and Development Center in California provides advanced engineering and development services for SP Manufacturing's global customers.  SAN DIEGO, Calif., Nov. 8, 2023 /PRNewswire/ -- SP Manufacturing, a leader in electronic manufacturing services for mission-critical industries, announc...

2023-11-08 10:00 1892

Docquity Expands Digitized Patient Access Programs To Enhance Healthcare Outcomes in Thailand

* After a successful pilot in the Philippines, five DocquityCare Patient Access Programs (PAPs)have been launched in Thailand * DocquityCare PAP will support more than 100 hospitals and 250 healthcare professionals (HCPs) to improve patient care for those with cancer and other life-threatenin...

2023-11-08 10:00 2350

WuXi Biologics Receives AAA MSCI ESG Rating

SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA rating from Morgan Stanley Capital International (MSCI) ESG Ratings, the highest rating for compan...

2023-11-08 08:30 1556

Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs

* During the event, Antengene will review promising data of its R&D pipeline, includingATG-031 (anti-CD24 monoclonal antibody), ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), ATG-037 (CD73 inhibitor), and ATG-008 (dual mTORC1/2 inhibitor). * The vir...

2023-11-08 08:30 1904

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

* ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years. * ESR1 mutations are present in up to 40% of ER+, HER2- advance...

2023-11-08 02:01 1768
1 ... 125126127128129130131 ... 611